Yazar "Demirkan, Fatih" seçeneğine göre listele

Listeleniyor 1 - 1 / 1
  • Küçük Resim
    Öğe
    Real life experience regarding clinical characteristics and treatment outcome in non-cutaneous peripheral t cell lymphomas: A multicenter study of Turkish hematology research and education group (threg)
    (Gelanos, 2022) Kayıkçı, Ömür; Özgür, Mehtap; Sarı, İsmail; Demirkan, Fatih; Beyan, Cengiz; Güven, Çetin; Vural, Filiz; Yılmaz, Mehmet; Öztürk, Erman; Akpınar, Seval; Eser, Bülent; Gündüz, Mehmet; Büyükaşık, Yahya; Payzın, Bahriye; Yıldırım, Rahşan; Doğu, Mehmet Hilmi; Özkan, Atilla; Kelkitli, Engin; Tekgündüz, Emre
    Objective: Peripheral T-NK-cell lymphomas (PTCL) are uncommon, quite heterogeneous group of disorders, and representing only 10–15% of all non-Hodgkin lymphomas (NHL). Although both molecular and clinical studies have been increased in recent years, we have still little knowledge regarding the real-life practice on PTCLs. In this study, we aimed to investigate the clinical characteristics and treatment outcomes in a large population-based cohort of patients presenting with systemic non-cutaneous PTCL patients. Material and methods: We conducted a multicenter retrospective analysis of 190 patients consecutively diagnosed and treated with non-cutaneous PTCLs between 2008 and 2016. Results: Considering all first-line treatment combinations, the overall response rate (ORR) was 65.9% with 49.4% complete remission (CR) (n=81) and 16.5% partial response (PR) (n=27). The 5-year OS and EFS rates were significantly different between the transplant and non-transplant groups (p<0.01, and p=0.033), respectively. Conclusion: Current retrospective large real-life data analysis of Turkish experience regarding the non-cutaneous PTCL patients showed consistent results compared to other unselected PTCL cohorts, with some minor differences in terms of survival and transplantation outcomes compared to existent experience. The long-term outcome of patients who received autologous hematopoietic cell transplantation as part of upfront consolidation or salvage is favorable compared to patients who were unable to receive high-dose therapy.